复方豨莶草胶囊对实验性大鼠急性痛风性关节炎细胞因子及COX-2表达影响的研究
|
摘要
目的：研究复方豨莶草胶囊治疗急性痛风性关节炎的作用机理。
方法：将复方豨莶草胶囊用于急性痛风性关节炎动物模型，通过足趾肿胀法、病理检查、ELISA酶联免疫法、免疫组织化学、RT-PCR等检测方法，测定细胞因子水平以及COX-2、VCAM-1和NF-KB的表达，并与抗炎药(扶他林)对照观察其对模型动物炎症的影响，并评价其抗炎效果。
结果：(1)复方豨莶草胶囊有明显的抗炎作用，可显著抑制痛风性关节炎大鼠踝关节肿胀，其抑制作用虽逊于扶他林，但其安全性高，大鼠无不良反应发生；(2)复方豨莶草胶囊能显著抑制痛风性关节炎大鼠病变关节局部炎性白细胞浸润及滑膜细胞的增生；(3)在病变关节局部，复方豨莶草胶囊能显著降低急性痛风性关节炎小鼠滑膜组织中组胺、IL-1β、IL-8、TNF-a含量，并降低关节滑膜内COX-2、VCAM-1和NF-κB的表达，从而抑止滑膜组织炎症发生。
结论：复方豨莶草胶囊治疗痛风性关节炎有确切疗效，可能与抑止组胺、IL-1β、IL-8、TNF-a的分泌以及COX-2、VCAM-1和NF-κB的表达有关。
Objective The aim of the study is to research the mechanism of therapyaction for acute gouty arthritis through complex prescription herbasiegesbeckiae capsule.
Methods The herb is used in the model of animal which get acute goutyarthritis. The method of the tumefaction on the toe of rats test, pathologicalexamination, ELISA euzymelinked immunosorbent assay, Immunohistochemistry, RT-PCR are used to determine the cytokine level andCOX-2, VCAM-1, NF-KB expression.We compare the treatment effect in rats ofherb to the effect of anti-inflammatory(Diclofenac) and evaluate the herb'scurative effect.
Results
1. The complex prescription herba siegesbeckiae capsule have evidentanti-inflammatory effect and can significant restrain the arthrocele ofankle-joints of rats which get acute gouty arthritis. The restrain effect is inferiorto the effect of Diclofenac, but herb is more safe and has no adverse effect..
2. The complex prescription herba siegesbeckiae capsule can significantrestrain leukocytic infiltrate of the rat's affection joints and the accrementitionof synovial cell of the rat's affection joints.
3. The complex prescription herba siegesbeckiae capsule can significantcut down the contents of beta-imidazolyle thylamine, IL-1β、IL-8、TNF-αofthe rats's affection joints membrana synovialis architecture, which can also cutdown COX-2, VCAM-1, NF-κB expression, then restrain the inflammation ofmembrana synovialis architecture.
Conclusion The complex prescription herba singesbeckiae capsule'santi-inflammation and analgesia mechanism may be related to inhibiting thebeta-imidazolyle thylamine, IL-1β、IL-8、TNF-αexcreting, acceleratingCOX-2、VCAM-1 and NF-κB expression.
方法：将复方豨莶草胶囊用于急性痛风性关节炎动物模型，通过足趾肿胀法、病理检查、ELISA酶联免疫法、免疫组织化学、RT-PCR等检测方法，测定细胞因子水平以及COX-2、VCAM-1和NF-KB的表达，并与抗炎药(扶他林)对照观察其对模型动物炎症的影响，并评价其抗炎效果。
结果：(1)复方豨莶草胶囊有明显的抗炎作用，可显著抑制痛风性关节炎大鼠踝关节肿胀，其抑制作用虽逊于扶他林，但其安全性高，大鼠无不良反应发生；(2)复方豨莶草胶囊能显著抑制痛风性关节炎大鼠病变关节局部炎性白细胞浸润及滑膜细胞的增生；(3)在病变关节局部，复方豨莶草胶囊能显著降低急性痛风性关节炎小鼠滑膜组织中组胺、IL-1β、IL-8、TNF-a含量，并降低关节滑膜内COX-2、VCAM-1和NF-κB的表达，从而抑止滑膜组织炎症发生。
结论：复方豨莶草胶囊治疗痛风性关节炎有确切疗效，可能与抑止组胺、IL-1β、IL-8、TNF-a的分泌以及COX-2、VCAM-1和NF-κB的表达有关。
Objective The aim of the study is to research the mechanism of therapyaction for acute gouty arthritis through complex prescription herbasiegesbeckiae capsule.
Methods The herb is used in the model of animal which get acute goutyarthritis. The method of the tumefaction on the toe of rats test, pathologicalexamination, ELISA euzymelinked immunosorbent assay, Immunohistochemistry, RT-PCR are used to determine the cytokine level andCOX-2, VCAM-1, NF-KB expression.We compare the treatment effect in rats ofherb to the effect of anti-inflammatory(Diclofenac) and evaluate the herb'scurative effect.
Results
1. The complex prescription herba siegesbeckiae capsule have evidentanti-inflammatory effect and can significant restrain the arthrocele ofankle-joints of rats which get acute gouty arthritis. The restrain effect is inferiorto the effect of Diclofenac, but herb is more safe and has no adverse effect..
2. The complex prescription herba siegesbeckiae capsule can significantrestrain leukocytic infiltrate of the rat's affection joints and the accrementitionof synovial cell of the rat's affection joints.
3. The complex prescription herba siegesbeckiae capsule can significantcut down the contents of beta-imidazolyle thylamine, IL-1β、IL-8、TNF-αofthe rats's affection joints membrana synovialis architecture, which can also cutdown COX-2, VCAM-1, NF-κB expression, then restrain the inflammation ofmembrana synovialis architecture.
Conclusion The complex prescription herba singesbeckiae capsule'santi-inflammation and analgesia mechanism may be related to inhibiting thebeta-imidazolyle thylamine, IL-1β、IL-8、TNF-αexcreting, acceleratingCOX-2、VCAM-1 and NF-κB expression.
引文
1． H.L.Yenl,C.H.Cheng and J.W.Lint Cervical Myelopathy due to Gouty Tophi in the Intervertebral Disc Space Acta Neurochir(alien)(2002) 144:205-207
2． Fenton P,Young S,Prutis K(1995) Gout of the spine.Two case reports and areview of the literature.J Bone Joint Surg Am 77:767-771
3． Kao MC,Huang SC,Chiu CT,Yao YT(2000) Thoracic cord compression due togout:A Case report and literature review.J Formos Med Assoc 997:572-575
4． Paquette S,Lath B,Guiot B(2000) Lumbar radiculopathy secondary to gouty tophi in the filum terminate in a patient without systemic gout:case report.Neurosurgery 464:986-988
5． Van De Laar MA,Van Soesbergen RM,Matricali B(1987) Tophaceous goutof the cervical spine without peripheral tophi.Arthritis Rheum 30:237-238 6． Barrett K,Miller ML,Wilson JT.Tophaceous gout of the spine mimicking epiduralinfection:case report and review of the literature.Neurosurgery 2001;,48:1170-1172．
7． Christine B.Chung Aurea Mohana-Borges Mini Pathria Tophaceous gout in anamputation stump in a patient with chronic myelogenous leukemia Skeletal Radiol(2003) 32:429-431 8． Dawn B,Williams JK,Walker SE.Prepatellar bursitis:a unique presentation oftophaceous gout in a normouricemic patient.J Rheumatol 1997,24:976-978．
9． Chaoui A,Garcia J,Kurt AM.Gouty tophus simulating soft tissue tumor in a hearttransplant recipient.Skeletal Radiol 1997,26:626--628．
10． Moura B,Rozenberg S,Fautrel B,Koeger AC,Bourgeois P.Pseudotumor of theknee in a kidney-pancreas transplant patient.J Rheumatol 2000;27:2520-2521．
11． 高铭文．痛风及痛风性关节炎,中华内科杂志,1958;11:1064 12． Roubenoff R(1990) Rheum Dis Clin North Am 16:539-550 13． Schumacher HR(1988) Primer on the rheumatic disease[M],9th edn.WilliamByrd press,USA,pp 198-210 14． Fang X(1983) Chin J Intern Med 22(7) :434-438
15. Harris CM, Lloyd DCEF, Lewis J (I995) J Clin Epidemiol 48(9):1153-1158
16. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DI, Giannini EH (1998) Arthritis Rheum 41:778-779
17. Chert Sl, Du H, Wang Y, Xu LQ (1998) Chin Med J 111:228-230
18．杨帕岩．唐福林．尹培达．21家医院痛风住院构成比15年变化趋势分析，中华流行病学杂志，1996，17(1)：10-12．
19．新加坡华文报刊资料7／8／1998 Pubism Page 22
20．王庆文等．原发性痛风的临床和流行痛学研究，中华内科杂志，2001，40(5)：313-315
21．孟昭享．痛风．北京医科大学中国协和医科大学联合出版社，1997，10
22．张浩宇等．痛风性关节炎的分子生物学基础，中国国伤，2001，14(3)：160-162
23．郑文浩等．痛风的治疗进展，中华医学杂志，2002，82(10)：716-717
24．寿涛等．吲哚美辛使用情况调查及严重副作用，中华风湿学杂志，2003，7(2)：109-110
25．马剑颖．痛风中医治疗研究进展，江苏中医药，2002，23(6)：40-41
26．唐丽．中医药外治痛风的临床进展．中国中医急症．2002，11(4)：298-299
27．裴长艳．中医约治疗痛风性关节炎的临床进展，中华中西医学杂志，2006，4(8)38-40
28．田财军，刘莹，陈宪海．痰毒与痛风，山东中医杂志，2001，20(3)：135．
29．袁曙光，张秋才．急性痛风从瘀论治，河北中医，2000，22(11)：837．
30．王秀莲．痛风病本虚标实论治探讨，山东中医杂志，2001，20(4)：199．
31．黄萌高．调脾益肾化湿泄浊法治疗痛风38例，实用中医药杂志，2001，17(5)：9．
32．李平庸．痛风汤治疗急性痛风性关节炎64例，湖南中医杂志，2004，20(1)：42-43．
33．王必中．浅述中医对痛风的认识及治疗，安徽中医学院学报，1992，(3)：12
34．高东祥，李荣秀．尹亚君教授辨治痛风病的经验，云南中医学报，2004，27(2)：44-45．
35．李安民，郑健功．痛风病证治探讨[J]，浙江中医杂志，2000，35(7)：299．
36．蒋唯强．试论痛风从脏腑辨证论治[J]，浙江中医杂志，2000，35(4)：168．
37．田财军．刘莹，陈宪海．痰毒与痛风，山东中医杂志，2001，20(3)：135．
38．骆传佳．何启会．祝佳．等．辨证与辨病相结合治疗痛风32例明，中国中医药信息杂志，2000，7(6)：60．
39．赵东鹰．血府逐瘀汤加减临床运用举隅[J]，安徽中医临床杂志．2000，12(5)：438．
40．兰友明．鲍雪娇．兰义明．滑石治疗痫风[J]，中医杂志．2000，41(5)：266．
41．倪青，任建文．时振声治疗痛风性肾病47例临床总结，北京中医，1997，16(1)：3．
42．赵兆琳．痛风灵治疗痛风性关节炎临床研究，上海中医药杂志，1996，12(I)：6
43．钟世耀．痛风辨治[J]．山东中医杂志，2002，21(11)：646—647
44．何浚治．痛风灵湿敷贴治疗痛风性关节炎168例，四川中医，1997，15(12)：43
45．吴国财．中医辨证分期治疗痛风性关节炎36例，中医研究，1999，12(2)：22-24
46．王秀莲．痛风病本虚标实论治探讨，山东中医杂志，2001，20(4)：199-200
47．倪毓生．四妙丸加味治疗急性痛风性关节炎34例，江苏中医，1988，2(9)：20
48．张文青．龙胆泻肝汤加减治疗急性痛风性关节炎临床观察，河北中医，2000，22(2)：132-133
49．王忆黎．严余明．痛风从毒论治的体会，中国中医药学报，2002，17(6)：364
50．史志云．中西医结合治疗痛风性关节炎9例报告，中国中西医结合杂志，1992，12(6)：273
51．李彤．《针灸化瘀通络法对痛风性关节炎及高尿酸血症影响的实验研究》，博士论文，2006，4(6)0-41
52．吕凤祥等．秦蚕汤治疗急性痛风性关节炎75例报告，中医正骨，1996，8(1)：23
53．陈国定等．辨证治痛风性关节炎42例，湖北中医杂志，1996，18(1)：40
54．李广征．中医辨证治疗痛凤24例，吉林中医药，1997，12．(2)23
55．郭裕和．从疲论治痛风性关节炎60例，贵阳中医学院学报，1998，20(3)：26
56．方策等．分型辨治痛风性关节炎11例，辽宁中医杂志，2000，27(2)：66
57．颜红红．辨证治疗痛风性关节炎34例临床观察，湖南中医学院学报，2000，20(2)：55
58．郑志永，齐雨．中医辨证治疗急性痛风性关节炎72例，吉林中医杂志，2003，23(3)：21
59．黄秀珍，陶雨药．辨证治疗痛风性关节炎56例临床观察，湖南中医杂志，2003，19(2)：23-24
60．梁健忠，劳国平．中药治疗急性痛风性关节炎临床观察，广西中医药，2002，25(6)：10-11
61．王秀莲．痛风本虚标实论治探讨，山东中医杂志，2001，20(4)：199—200
62．吴国财．中医辨证分期治疗痛风性关节炎36例，中医研究，1999，(12)2：22
63．哇承志等．活血利水汉治疗痛风性关节炎，四川中医，1997，15(10)：21
64．刘和平．加味当归四逆汤治疗痛风性关节炎36例，湖南中医杂志，1999，15(4)：47
65．曹祥永，张圣华，陈小红．痛风病中医证治体会，实用中医药杂志，2003，19(4)：210-211
66．李学爽，向建敏等．知柏地黄丸加味治疗痛风性关节炎的疗效观察，河北中医，1997，19(2)：39-40
67．马剑颖，刘友章，周正．痛风康治疗急性痛风性关节炎的临床观察，中国中西医结合杂志，2004，24(6)：488-490
68．冈内宣三．大柴胡汤去大黄对防止痛风发作、降低尿酸值有效，汉方研究，1992，(1)：13
69．孙效言，周广莲．四妙丸加味治疗痛风[J]，浙江中医杂志，2000，35(4)：169
70．徐天景，陈志伟．桂枝芍药知母汤加减治疗急性痛风45例疗效观察[J]，浙江中医学院学报，1998，22(4)：19
71．张明，金若敏，王红梅等．痛风冲剂对急性痛风性关节炎抗炎作用的研究 天津中医药，2003，20(4)：32-35
72．姚桂荣，王长春．加味宣痹汤治疗痛风46例[J]，湖北中医杂志，2000，22(4)：35
73．武胜，苏小静等．中西医结合治疗原发性痛风临床研究，宁夏医学杂志，1999，21(6)333-334
74．杨祖轩．中西医结合治疗痛风临床观察，中国校医，2000，14(5)：354
75．赵晓刚，王新华．中西医结合治疗痛风20例临床观察，中国中医药科技，2000，7(4)：220
76．姚睿智，程宇星．双柏油膏为主治疗痛风性关节炎急性发作49例疗效观察，新中医，2003，35(10)：28-29
77．李学卿．中药辨证内服加中药电泳浴治疗痛风性关节炎42例，河北中医，2004，26(5)：339-340．
78．孙东云，邵立娟，王艳君．中药内服外敷治疗痛风性关节炎急性发作24例，河北中医，2004，26(2)：103-104．
89．雷玉慧，崔忠志，原质等．中药内外合治法治疗痛风性关节炎30例，实用中医内科杂志，2004，18(4)：347．
80．黄献民．痛风性关节炎的辨证治疗，新中医，1997，29(6)：47
81．夏金华．内外并治痛风100例，江苏中医，1994，15(12)：13．
82．段和平，赵毓荣．湿热毒瘀论治痛风性关节炎体会，中国中西医结合杂志，1993，13(11)：693
83．洪国章．四妙散加味治疗痛风20例，浙江中医杂志，1991，26(6)：276．
84．施财富．中药熏蒸治疗痛风性关节炎42例临床观察，江苏中医药，2004，25，(9)：34-35
85．晏建立，程繁荣，王新建等．乐尔膏穴位敷贴治疗痛风性关节疼痛60例，新中医，2000，32(6)：22．
86. T. Nakamura, Nippon Naika Gakkai Zasshi, 85, No. 9, 1520-1527 (1996).
87. M. Wyndham, Practitioner, 242, No. 1588, 546 (1998).
88. A. Colin Buck Gout-the "at your finger tips" guide byR. Grahame, H.A.Simmonds, E. Carrey Urol Res (2004) 32: 249.
89．杜蕙，陈顺乐，王元等．上海市黄浦区社区高尿酸血症与痛风流行病学调查，中华风湿病学杂志，1998，2(2)：75-78．
90．王庆文等．原发性痛风的临床和流行病学研究，中华内科杂志，2001，40(5)：313-315．
91. Robbins SL, Contran RS, Kumar V (1984) In: Robbins SL, Contran RS, Kumar V(eds) Pathologic basis of disease, 3rd edn. WB Saunders Co, Philadelphia, pp1356-1362
92. Chert LFC, Seaborn CD (1996) J Am Diet Assoc 96:34
93. Eastmond CJ, Graton M, Robins S, Riddoch S (1995) The effects of alcoholicbeverages on orate metabolism in gout sufferers. Br J Rheumatol 34:756-759
94. Kazuko M, Hiroshi M, Toshio O, Tuck ML (2002) Am J Hypertens 15:189
95. Costa A, Igual I, Bedini J, Quint L, Conget I (2002) Metabolism 51:372-375
96. moue K, Namilci T, lwasaki Y, Yoshimura Y, Nakazawa H (2003) J ChromatogrB785: 57-63
97. The Expert Panel (1988) Report of the National Cholesterol Education Programexpert panel on detection, evaluation and treatment of high blood cholesterol in adults.Arch Intern Med 148:36-69
98. Scott JT (1977) Obesity and hyperuricaemia. Clin Rheum Dis 3:23-35
99. Hoieggen A, Eldsen SE, Julius S, Devereux RB, Alderman M, Chen C, DahlofB (2003) Am J Hypertens 16:A9
100. Kirschbaum B (2001) Med Hypotheses 56:625-629
101. Iribarren C,Sharpb DS, Curbc JD, Yano K (1996) J Clinical Epidemiology 49: 673-678
102. DobsonA (1999) Lancet 354:1578
103. Abbott RD, Brand FN, Kannel WB, Castelli WP (1988) Gout and coronary arterydisease: the Framingham Study. J Clin Epidemiol 41:237-242
104. Alderman M (1999) Uric acid in hypertension and cardiovascular disease. Can J Cardiol 15(Suppl F): 20-25
105. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality. TheNHANES. Epidemiologic follow-up study 1971-92. JAMA 283:2404-10
106．孟昭亨．痛风，北京医科大学中国协和医科大学联合出版社，1997．90
107. Terkeltaub R.Pathogenesis andtreatment crystal-induced inflammation. Ln:Koopman WJ. editor. Arthritis and allied conditions: ate Ytbook of rheumatology. Baltimore: Williams and Wilkins 1996,10:208
108．郝丽荣，吕松岑等．西拉普利、氯沙坦对尿酸肾病大鼠肾上皮细胞生长因子((EGF)和成纤维细胞生长因子(bFGF)mRNA表达的影响，高血压杂志，2004，12(5)：436-441
109．徐红，王开贞，王玉奎．临床常用药物第2版，山东科学技术出版社，2004．
110．赵泉霖，郝亮．原发性高尿酸血症辨治初探，山东中医杂志，2005，24(8)：453-454
111. Neil W. McGill Gout and other crystal-associated arthropathies Baillie areClinicalRheumatology, 2000, 14(3):445-460
112．田国庆．中医辨证及治疗痛风研究近况，医学研究通讯，1995，24(4)：18
113．田财军．痛风从内毒论治的临床研究，山东中医药大学学报，2002，26(5)：369-371
114．曲环汝等．痛风论治探析．辽宁中医杂忐，2002，29(7)23
115．徐叔云．药理实验方法学，北京，人民卫生出版社，1995．532
116．王浴生等主编．中药药理与应用，北京人民卫生出版社，1998，(2)：64-65
117．徐叔云主编．药理实验方法学，北京人民卫生出版社，1995，32
118．赵圣川．痛风的诊断与治疗，北京军事医学科学出版社，2002，19-20
119. Coderre TJ, Wall PD. Ankle joint arthritis in rats:Analternative animal modle of arthritis to that produce by Freud'sadjuvant. Pain, 1987,28:379-393
120．孟昭亨主编．痛风，北京：北京医科大学中国协和医科大学联合出版社，1997，285
121．殷凯生．组胺研究进展近况，国外医学·生理病理学科分册，1983，3(4)：180-183
122. Shrestha M,Chiu MJ,Martin RL,et al.Treatment of acute gouty arthritis with intramuscularke toralactromethamine. AmJEmergMed,1994,12:454-5
123. Terkeltaub. R. Pathogenesis and treatment ofcrystal-inducedinflammation. In: Koopman WJ. editor. Arthritis and allied conditions: a textbookof rheumatology.Baltimore: Williams and Witkins, 1996, 10:2085.
124. Terkeltaub R,Baird S,Sears P, et al.The marine homolog of the in teroerkin-preceptor cxcrz is essential for the occurrence of neutrophilic inflammation in airpouch model of acute urate crystal-induced gouty synoritis. Arthritis Rheum,1998, 41(5):900.
125. Baggioline M, Dewald B, Mosey B. IL-8 and related chemotactic cytokines CXCand Chhemokines. Adv Immunol,1994,55:97-179.
126. Nishimura A,Akahoshi T, Takahashi M,et al.Attenuation of monosodium uratcrystal induced arthritis in rabbits by neuralizing antibody against IT 8.J LeukocBiol,1997,62:441-449.
127. MatsukawaA,YoshimuraT, MaedaT, et al. Neutrophil accumulation andactiviation by homologons IL-8 in rabbits: IL-8 induced destruction of cartiologeand produced of IL-1 and IL-1 Ra in vivo. J Immunol,1995,154: 5419-5424
128. Harris MD. Siegel LB. Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999, 59(4):925-34
129. Perez-Ruiz F. Calabozo M. Herrero-Beites AM. et a Improvementof renal function in patients withchronic gout after proper control of hyperuricemia and gouty bouts. 2000,86(3):287-91
130. Pouliot M, James MJ, McColl SR et al. Monosodium urate microcrystals induce cyclooxygenasez inhuman monocytes.Blood.1998,91( 5) :1769-76 131． Molad Y.Update on colchicine and its mechanism of action.Curr Rheumatol Rep,2002,4(3) :252
132． Riendeau D,Percival MD Brideau C.et al.Etoricoxib(1) -0663) :preclinical profile and comparisonwith other agents that selectively inhibit cyclooxygenase-2． J Pharmacol Exp Therapeutics.2001,296:558-66
133． Li Z,Davis GS,Mohr C.Inhibition of LPS-induced tumor necrosis factoraprodu-ction colchicineand other microtubules disrupting drugs.Immunobiology,1996,195:624-39
134． Di Giovine FS,Malawista SE,Thomton E,et al.Urate crystals stimulate production of tumor necrosis
135． Bohn C.Davis Jr.A practicalap proach to gout Current mannt of an old disease.Postgrad Med,1999,106(4) :115-23
136． Shrestha M Chiu MJ Martin RL et al.Treatment of acute gouty arthritis with intramuscular ketoralac tromethamine.Am JEmerg Med 1994,12:454-5
137． Perez-Ruiz F.Calabozo M.Herrero-Beites AM.et al.Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts,ron.2000,86(3) :287-91
138． Akihiro Mastsukawa Teizo Yoshimura Kazuhiko Miyamoto,et al.Analysis of the Inflammatory Cytokine Network among TNF-a,IL-1β,IL-1receptor antagonist,and IL-8 i n LPS Induced RabbitArthritis.Labora HoryInvestigation.1997,76(50) :629
139． Xing Z,Kirpalau H.Torry Detal:polymorpho nuclear leukocytesasa significant source of tumor necrosis factor alpha in endotoxin challenged lung tissue.Am J Pathol,1993,143(4) :1009-1016
140． Baggioline M,Dewald B,mosey B.IL-8 and related chemotactic cytokines CXC and Chemokines.AdvImmunol,1994,55:97-179
141． Nishimura A,Akahoshi T,Takahashi M,et alAttenuation of monosodium urate crystal inducedarthritis in rabbits by neuralizing antibody againstb IL-8． J Leukoc Biol,1997,62:441-449
142． Matsukawa A,Yoshimura T,Maeda T,et alNeutrophil accumalation and activiation byhomologons IL-8 in rabbits:IL-8 induced destructionof cartiologe and produced of IL-1 and IL-1 Ra in vivo.JImmunol,1995,154:5419-5424
143． Di Giovine FS,Malawista SE,Nuki G,et allntereukin-1(IL-1) as a mediatorcrystal arthritis:Stimulation of T cell and synovialfibroblast mitogenssis by urate crystal-induced IL-1． J Immunol,1987,138:3213-3218
144． Terkeltaub RA,Zachariae C,Santoro D,et al.Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation.Arthritis Rheum,1991,34(7) :894-903．
145 Woolf AD,Dieppe PA.Mediators of crystal-induced inflammation in the joint.Br Med Bull,1987,43(2) :429-444．
146． Funk CD,Funk LB,Kennedy ME,et al.Human platelet/erythroleukemiacell prostaglandin G/H synthase:DNA cloning,expression,and genechromo-somal assignment.FASEB J,1991,5:2304-2312．
147． Herschman HR.Prostaglandin synthase.Z.Biochim Biophys Acta,1996,299(1) :125-140．
148． Williams CS,Dubois RN.Prostaglandin endoperoxide synthase.Why twoiso-forms.Am J Physiol,1996,270(30) :393-400．
149． Myers LK,Kang AH,Postlethwaite AE,et al.The genetic ablation of cyclooxygenase-2 prevents the development of autoimmune arthritis.Arthritis Rheum,2000,43(12) :2687-2693．
150． Pouliot M,James MJ,McColl SR,et al.Monosodium orate microcrystals cyclooxygenase-2 in human monocytes.Blood,1998,91(5) :1769-1776．
151． Tsujii M,DuBois RN.Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase Cell,1995,83(3) :493-501．
152． Tsujii M,Kawano S,DuBois RN,etal.Cyclooxygenase regulationv angioge-nesis induced by colon cancer cells.Cel 1,1998,93(5) :705-716．
153． Sell R,Baltimore D Inducitbility of kappa immunoglobulin enhancerbinling protein NF-kappa by a post-translational mechanism.Cell.1986,47:92 1-928．
154． Baeuerle PA,Henkei T.Function and activation of NF-kappa B in theimmune system[J].Annu Rev Immunol,1 994,12:141-179
155． Goebeler M,et al.Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyteprotein-1 gene in primary endothelial cells[J]Blood,2001,97(1) :46-55
156． Ghosh G.NF-kappa B and RPJ pmteins:evolutionary conserved mediators of the immune response.Annu Rev Inmmunol,1998,16:225．
157． Gawaz M,Brand K,Dickfeld T ,et al .Platelets induce alterations ofchemotactic and adhesive properties of endotheiial cells mediated through an interleukin dependent mechanism.Implications for atherogenesis[J].Atherogenesis,2000,148:75-851
158． Wong CK,Ip WK Lam CW.Interleukin,and granulocyte macrophage colony-stimulating factor-induced adhesion molecule ex pression on eosinophils by mitogen-activated protein kinase andnuclear factor kappa B[J].American Journal of Respiratory Cell & Molecular Biology ,2003,29(1) :143-147
159． Gorgoulis VG,Zacharatos P,Kotsinas A,et al.activates ICAM-1(CD54) expression in an NF.KappaB.independent manner[J]EM2 BO Journal 2003 ,22(7) :1567-15781
160． Salvemini D,Manning PT,Zweifel BS,et al.Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties of nitric oxide synthase inhibitors.J Clin Invest,1995,96(1) :301-308．
161． Jarvinen TA,Moilanen T,Jarvinen TL,et al.Endogenous nitric oxide and prosta-glandin E_2 do not regulate the synthesis of each other in interleukin-1 betasti-mulated rat articular cartilage.Inflammation,1996,20(6) :683-692．
2． Fenton P,Young S,Prutis K(1995) Gout of the spine.Two case reports and areview of the literature.J Bone Joint Surg Am 77:767-771
3． Kao MC,Huang SC,Chiu CT,Yao YT(2000) Thoracic cord compression due togout:A Case report and literature review.J Formos Med Assoc 997:572-575
4． Paquette S,Lath B,Guiot B(2000) Lumbar radiculopathy secondary to gouty tophi in the filum terminate in a patient without systemic gout:case report.Neurosurgery 464:986-988
5． Van De Laar MA,Van Soesbergen RM,Matricali B(1987) Tophaceous goutof the cervical spine without peripheral tophi.Arthritis Rheum 30:237-238 6． Barrett K,Miller ML,Wilson JT.Tophaceous gout of the spine mimicking epiduralinfection:case report and review of the literature.Neurosurgery 2001;,48:1170-1172．
7． Christine B.Chung Aurea Mohana-Borges Mini Pathria Tophaceous gout in anamputation stump in a patient with chronic myelogenous leukemia Skeletal Radiol(2003) 32:429-431 8． Dawn B,Williams JK,Walker SE.Prepatellar bursitis:a unique presentation oftophaceous gout in a normouricemic patient.J Rheumatol 1997,24:976-978．
9． Chaoui A,Garcia J,Kurt AM.Gouty tophus simulating soft tissue tumor in a hearttransplant recipient.Skeletal Radiol 1997,26:626--628．
10． Moura B,Rozenberg S,Fautrel B,Koeger AC,Bourgeois P.Pseudotumor of theknee in a kidney-pancreas transplant patient.J Rheumatol 2000;27:2520-2521．
11． 高铭文．痛风及痛风性关节炎,中华内科杂志,1958;11:1064 12． Roubenoff R(1990) Rheum Dis Clin North Am 16:539-550 13． Schumacher HR(1988) Primer on the rheumatic disease[M],9th edn.WilliamByrd press,USA,pp 198-210 14． Fang X(1983) Chin J Intern Med 22(7) :434-438
15. Harris CM, Lloyd DCEF, Lewis J (I995) J Clin Epidemiol 48(9):1153-1158
16. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DI, Giannini EH (1998) Arthritis Rheum 41:778-779
17. Chert Sl, Du H, Wang Y, Xu LQ (1998) Chin Med J 111:228-230
18．杨帕岩．唐福林．尹培达．21家医院痛风住院构成比15年变化趋势分析，中华流行病学杂志，1996，17(1)：10-12．
19．新加坡华文报刊资料7／8／1998 Pubism Page 22
20．王庆文等．原发性痛风的临床和流行痛学研究，中华内科杂志，2001，40(5)：313-315
21．孟昭享．痛风．北京医科大学中国协和医科大学联合出版社，1997，10
22．张浩宇等．痛风性关节炎的分子生物学基础，中国国伤，2001，14(3)：160-162
23．郑文浩等．痛风的治疗进展，中华医学杂志，2002，82(10)：716-717
24．寿涛等．吲哚美辛使用情况调查及严重副作用，中华风湿学杂志，2003，7(2)：109-110
25．马剑颖．痛风中医治疗研究进展，江苏中医药，2002，23(6)：40-41
26．唐丽．中医药外治痛风的临床进展．中国中医急症．2002，11(4)：298-299
27．裴长艳．中医约治疗痛风性关节炎的临床进展，中华中西医学杂志，2006，4(8)38-40
28．田财军，刘莹，陈宪海．痰毒与痛风，山东中医杂志，2001，20(3)：135．
29．袁曙光，张秋才．急性痛风从瘀论治，河北中医，2000，22(11)：837．
30．王秀莲．痛风病本虚标实论治探讨，山东中医杂志，2001，20(4)：199．
31．黄萌高．调脾益肾化湿泄浊法治疗痛风38例，实用中医药杂志，2001，17(5)：9．
32．李平庸．痛风汤治疗急性痛风性关节炎64例，湖南中医杂志，2004，20(1)：42-43．
33．王必中．浅述中医对痛风的认识及治疗，安徽中医学院学报，1992，(3)：12
34．高东祥，李荣秀．尹亚君教授辨治痛风病的经验，云南中医学报，2004，27(2)：44-45．
35．李安民，郑健功．痛风病证治探讨[J]，浙江中医杂志，2000，35(7)：299．
36．蒋唯强．试论痛风从脏腑辨证论治[J]，浙江中医杂志，2000，35(4)：168．
37．田财军．刘莹，陈宪海．痰毒与痛风，山东中医杂志，2001，20(3)：135．
38．骆传佳．何启会．祝佳．等．辨证与辨病相结合治疗痛风32例明，中国中医药信息杂志，2000，7(6)：60．
39．赵东鹰．血府逐瘀汤加减临床运用举隅[J]，安徽中医临床杂志．2000，12(5)：438．
40．兰友明．鲍雪娇．兰义明．滑石治疗痫风[J]，中医杂志．2000，41(5)：266．
41．倪青，任建文．时振声治疗痛风性肾病47例临床总结，北京中医，1997，16(1)：3．
42．赵兆琳．痛风灵治疗痛风性关节炎临床研究，上海中医药杂志，1996，12(I)：6
43．钟世耀．痛风辨治[J]．山东中医杂志，2002，21(11)：646—647
44．何浚治．痛风灵湿敷贴治疗痛风性关节炎168例，四川中医，1997，15(12)：43
45．吴国财．中医辨证分期治疗痛风性关节炎36例，中医研究，1999，12(2)：22-24
46．王秀莲．痛风病本虚标实论治探讨，山东中医杂志，2001，20(4)：199-200
47．倪毓生．四妙丸加味治疗急性痛风性关节炎34例，江苏中医，1988，2(9)：20
48．张文青．龙胆泻肝汤加减治疗急性痛风性关节炎临床观察，河北中医，2000，22(2)：132-133
49．王忆黎．严余明．痛风从毒论治的体会，中国中医药学报，2002，17(6)：364
50．史志云．中西医结合治疗痛风性关节炎9例报告，中国中西医结合杂志，1992，12(6)：273
51．李彤．《针灸化瘀通络法对痛风性关节炎及高尿酸血症影响的实验研究》，博士论文，2006，4(6)0-41
52．吕凤祥等．秦蚕汤治疗急性痛风性关节炎75例报告，中医正骨，1996，8(1)：23
53．陈国定等．辨证治痛风性关节炎42例，湖北中医杂志，1996，18(1)：40
54．李广征．中医辨证治疗痛凤24例，吉林中医药，1997，12．(2)23
55．郭裕和．从疲论治痛风性关节炎60例，贵阳中医学院学报，1998，20(3)：26
56．方策等．分型辨治痛风性关节炎11例，辽宁中医杂志，2000，27(2)：66
57．颜红红．辨证治疗痛风性关节炎34例临床观察，湖南中医学院学报，2000，20(2)：55
58．郑志永，齐雨．中医辨证治疗急性痛风性关节炎72例，吉林中医杂志，2003，23(3)：21
59．黄秀珍，陶雨药．辨证治疗痛风性关节炎56例临床观察，湖南中医杂志，2003，19(2)：23-24
60．梁健忠，劳国平．中药治疗急性痛风性关节炎临床观察，广西中医药，2002，25(6)：10-11
61．王秀莲．痛风本虚标实论治探讨，山东中医杂志，2001，20(4)：199—200
62．吴国财．中医辨证分期治疗痛风性关节炎36例，中医研究，1999，(12)2：22
63．哇承志等．活血利水汉治疗痛风性关节炎，四川中医，1997，15(10)：21
64．刘和平．加味当归四逆汤治疗痛风性关节炎36例，湖南中医杂志，1999，15(4)：47
65．曹祥永，张圣华，陈小红．痛风病中医证治体会，实用中医药杂志，2003，19(4)：210-211
66．李学爽，向建敏等．知柏地黄丸加味治疗痛风性关节炎的疗效观察，河北中医，1997，19(2)：39-40
67．马剑颖，刘友章，周正．痛风康治疗急性痛风性关节炎的临床观察，中国中西医结合杂志，2004，24(6)：488-490
68．冈内宣三．大柴胡汤去大黄对防止痛风发作、降低尿酸值有效，汉方研究，1992，(1)：13
69．孙效言，周广莲．四妙丸加味治疗痛风[J]，浙江中医杂志，2000，35(4)：169
70．徐天景，陈志伟．桂枝芍药知母汤加减治疗急性痛风45例疗效观察[J]，浙江中医学院学报，1998，22(4)：19
71．张明，金若敏，王红梅等．痛风冲剂对急性痛风性关节炎抗炎作用的研究 天津中医药，2003，20(4)：32-35
72．姚桂荣，王长春．加味宣痹汤治疗痛风46例[J]，湖北中医杂志，2000，22(4)：35
73．武胜，苏小静等．中西医结合治疗原发性痛风临床研究，宁夏医学杂志，1999，21(6)333-334
74．杨祖轩．中西医结合治疗痛风临床观察，中国校医，2000，14(5)：354
75．赵晓刚，王新华．中西医结合治疗痛风20例临床观察，中国中医药科技，2000，7(4)：220
76．姚睿智，程宇星．双柏油膏为主治疗痛风性关节炎急性发作49例疗效观察，新中医，2003，35(10)：28-29
77．李学卿．中药辨证内服加中药电泳浴治疗痛风性关节炎42例，河北中医，2004，26(5)：339-340．
78．孙东云，邵立娟，王艳君．中药内服外敷治疗痛风性关节炎急性发作24例，河北中医，2004，26(2)：103-104．
89．雷玉慧，崔忠志，原质等．中药内外合治法治疗痛风性关节炎30例，实用中医内科杂志，2004，18(4)：347．
80．黄献民．痛风性关节炎的辨证治疗，新中医，1997，29(6)：47
81．夏金华．内外并治痛风100例，江苏中医，1994，15(12)：13．
82．段和平，赵毓荣．湿热毒瘀论治痛风性关节炎体会，中国中西医结合杂志，1993，13(11)：693
83．洪国章．四妙散加味治疗痛风20例，浙江中医杂志，1991，26(6)：276．
84．施财富．中药熏蒸治疗痛风性关节炎42例临床观察，江苏中医药，2004，25，(9)：34-35
85．晏建立，程繁荣，王新建等．乐尔膏穴位敷贴治疗痛风性关节疼痛60例，新中医，2000，32(6)：22．
86. T. Nakamura, Nippon Naika Gakkai Zasshi, 85, No. 9, 1520-1527 (1996).
87. M. Wyndham, Practitioner, 242, No. 1588, 546 (1998).
88. A. Colin Buck Gout-the "at your finger tips" guide byR. Grahame, H.A.Simmonds, E. Carrey Urol Res (2004) 32: 249.
89．杜蕙，陈顺乐，王元等．上海市黄浦区社区高尿酸血症与痛风流行病学调查，中华风湿病学杂志，1998，2(2)：75-78．
90．王庆文等．原发性痛风的临床和流行病学研究，中华内科杂志，2001，40(5)：313-315．
91. Robbins SL, Contran RS, Kumar V (1984) In: Robbins SL, Contran RS, Kumar V(eds) Pathologic basis of disease, 3rd edn. WB Saunders Co, Philadelphia, pp1356-1362
92. Chert LFC, Seaborn CD (1996) J Am Diet Assoc 96:34
93. Eastmond CJ, Graton M, Robins S, Riddoch S (1995) The effects of alcoholicbeverages on orate metabolism in gout sufferers. Br J Rheumatol 34:756-759
94. Kazuko M, Hiroshi M, Toshio O, Tuck ML (2002) Am J Hypertens 15:189
95. Costa A, Igual I, Bedini J, Quint L, Conget I (2002) Metabolism 51:372-375
96. moue K, Namilci T, lwasaki Y, Yoshimura Y, Nakazawa H (2003) J ChromatogrB785: 57-63
97. The Expert Panel (1988) Report of the National Cholesterol Education Programexpert panel on detection, evaluation and treatment of high blood cholesterol in adults.Arch Intern Med 148:36-69
98. Scott JT (1977) Obesity and hyperuricaemia. Clin Rheum Dis 3:23-35
99. Hoieggen A, Eldsen SE, Julius S, Devereux RB, Alderman M, Chen C, DahlofB (2003) Am J Hypertens 16:A9
100. Kirschbaum B (2001) Med Hypotheses 56:625-629
101. Iribarren C,Sharpb DS, Curbc JD, Yano K (1996) J Clinical Epidemiology 49: 673-678
102. DobsonA (1999) Lancet 354:1578
103. Abbott RD, Brand FN, Kannel WB, Castelli WP (1988) Gout and coronary arterydisease: the Framingham Study. J Clin Epidemiol 41:237-242
104. Alderman M (1999) Uric acid in hypertension and cardiovascular disease. Can J Cardiol 15(Suppl F): 20-25
105. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality. TheNHANES. Epidemiologic follow-up study 1971-92. JAMA 283:2404-10
106．孟昭亨．痛风，北京医科大学中国协和医科大学联合出版社，1997．90
107. Terkeltaub R.Pathogenesis andtreatment crystal-induced inflammation. Ln:Koopman WJ. editor. Arthritis and allied conditions: ate Ytbook of rheumatology. Baltimore: Williams and Wilkins 1996,10:208
108．郝丽荣，吕松岑等．西拉普利、氯沙坦对尿酸肾病大鼠肾上皮细胞生长因子((EGF)和成纤维细胞生长因子(bFGF)mRNA表达的影响，高血压杂志，2004，12(5)：436-441
109．徐红，王开贞，王玉奎．临床常用药物第2版，山东科学技术出版社，2004．
110．赵泉霖，郝亮．原发性高尿酸血症辨治初探，山东中医杂志，2005，24(8)：453-454
111. Neil W. McGill Gout and other crystal-associated arthropathies Baillie areClinicalRheumatology, 2000, 14(3):445-460
112．田国庆．中医辨证及治疗痛风研究近况，医学研究通讯，1995，24(4)：18
113．田财军．痛风从内毒论治的临床研究，山东中医药大学学报，2002，26(5)：369-371
114．曲环汝等．痛风论治探析．辽宁中医杂忐，2002，29(7)23
115．徐叔云．药理实验方法学，北京，人民卫生出版社，1995．532
116．王浴生等主编．中药药理与应用，北京人民卫生出版社，1998，(2)：64-65
117．徐叔云主编．药理实验方法学，北京人民卫生出版社，1995，32
118．赵圣川．痛风的诊断与治疗，北京军事医学科学出版社，2002，19-20
119. Coderre TJ, Wall PD. Ankle joint arthritis in rats:Analternative animal modle of arthritis to that produce by Freud'sadjuvant. Pain, 1987,28:379-393
120．孟昭亨主编．痛风，北京：北京医科大学中国协和医科大学联合出版社，1997，285
121．殷凯生．组胺研究进展近况，国外医学·生理病理学科分册，1983，3(4)：180-183
122. Shrestha M,Chiu MJ,Martin RL,et al.Treatment of acute gouty arthritis with intramuscularke toralactromethamine. AmJEmergMed,1994,12:454-5
123. Terkeltaub. R. Pathogenesis and treatment ofcrystal-inducedinflammation. In: Koopman WJ. editor. Arthritis and allied conditions: a textbookof rheumatology.Baltimore: Williams and Witkins, 1996, 10:2085.
124. Terkeltaub R,Baird S,Sears P, et al.The marine homolog of the in teroerkin-preceptor cxcrz is essential for the occurrence of neutrophilic inflammation in airpouch model of acute urate crystal-induced gouty synoritis. Arthritis Rheum,1998, 41(5):900.
125. Baggioline M, Dewald B, Mosey B. IL-8 and related chemotactic cytokines CXCand Chhemokines. Adv Immunol,1994,55:97-179.
126. Nishimura A,Akahoshi T, Takahashi M,et al.Attenuation of monosodium uratcrystal induced arthritis in rabbits by neuralizing antibody against IT 8.J LeukocBiol,1997,62:441-449.
127. MatsukawaA,YoshimuraT, MaedaT, et al. Neutrophil accumulation andactiviation by homologons IL-8 in rabbits: IL-8 induced destruction of cartiologeand produced of IL-1 and IL-1 Ra in vivo. J Immunol,1995,154: 5419-5424
128. Harris MD. Siegel LB. Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999, 59(4):925-34
129. Perez-Ruiz F. Calabozo M. Herrero-Beites AM. et a Improvementof renal function in patients withchronic gout after proper control of hyperuricemia and gouty bouts. 2000,86(3):287-91
130. Pouliot M, James MJ, McColl SR et al. Monosodium urate microcrystals induce cyclooxygenasez inhuman monocytes.Blood.1998,91( 5) :1769-76 131． Molad Y.Update on colchicine and its mechanism of action.Curr Rheumatol Rep,2002,4(3) :252
132． Riendeau D,Percival MD Brideau C.et al.Etoricoxib(1) -0663) :preclinical profile and comparisonwith other agents that selectively inhibit cyclooxygenase-2． J Pharmacol Exp Therapeutics.2001,296:558-66
133． Li Z,Davis GS,Mohr C.Inhibition of LPS-induced tumor necrosis factoraprodu-ction colchicineand other microtubules disrupting drugs.Immunobiology,1996,195:624-39
134． Di Giovine FS,Malawista SE,Thomton E,et al.Urate crystals stimulate production of tumor necrosis
135． Bohn C.Davis Jr.A practicalap proach to gout Current mannt of an old disease.Postgrad Med,1999,106(4) :115-23
136． Shrestha M Chiu MJ Martin RL et al.Treatment of acute gouty arthritis with intramuscular ketoralac tromethamine.Am JEmerg Med 1994,12:454-5
137． Perez-Ruiz F.Calabozo M.Herrero-Beites AM.et al.Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts,ron.2000,86(3) :287-91
138． Akihiro Mastsukawa Teizo Yoshimura Kazuhiko Miyamoto,et al.Analysis of the Inflammatory Cytokine Network among TNF-a,IL-1β,IL-1receptor antagonist,and IL-8 i n LPS Induced RabbitArthritis.Labora HoryInvestigation.1997,76(50) :629
139． Xing Z,Kirpalau H.Torry Detal:polymorpho nuclear leukocytesasa significant source of tumor necrosis factor alpha in endotoxin challenged lung tissue.Am J Pathol,1993,143(4) :1009-1016
140． Baggioline M,Dewald B,mosey B.IL-8 and related chemotactic cytokines CXC and Chemokines.AdvImmunol,1994,55:97-179
141． Nishimura A,Akahoshi T,Takahashi M,et alAttenuation of monosodium urate crystal inducedarthritis in rabbits by neuralizing antibody againstb IL-8． J Leukoc Biol,1997,62:441-449
142． Matsukawa A,Yoshimura T,Maeda T,et alNeutrophil accumalation and activiation byhomologons IL-8 in rabbits:IL-8 induced destructionof cartiologe and produced of IL-1 and IL-1 Ra in vivo.JImmunol,1995,154:5419-5424
143． Di Giovine FS,Malawista SE,Nuki G,et allntereukin-1(IL-1) as a mediatorcrystal arthritis:Stimulation of T cell and synovialfibroblast mitogenssis by urate crystal-induced IL-1． J Immunol,1987,138:3213-3218
144． Terkeltaub RA,Zachariae C,Santoro D,et al.Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation.Arthritis Rheum,1991,34(7) :894-903．
145 Woolf AD,Dieppe PA.Mediators of crystal-induced inflammation in the joint.Br Med Bull,1987,43(2) :429-444．
146． Funk CD,Funk LB,Kennedy ME,et al.Human platelet/erythroleukemiacell prostaglandin G/H synthase:DNA cloning,expression,and genechromo-somal assignment.FASEB J,1991,5:2304-2312．
147． Herschman HR.Prostaglandin synthase.Z.Biochim Biophys Acta,1996,299(1) :125-140．
148． Williams CS,Dubois RN.Prostaglandin endoperoxide synthase.Why twoiso-forms.Am J Physiol,1996,270(30) :393-400．
149． Myers LK,Kang AH,Postlethwaite AE,et al.The genetic ablation of cyclooxygenase-2 prevents the development of autoimmune arthritis.Arthritis Rheum,2000,43(12) :2687-2693．
150． Pouliot M,James MJ,McColl SR,et al.Monosodium orate microcrystals cyclooxygenase-2 in human monocytes.Blood,1998,91(5) :1769-1776．
151． Tsujii M,DuBois RN.Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase Cell,1995,83(3) :493-501．
152． Tsujii M,Kawano S,DuBois RN,etal.Cyclooxygenase regulationv angioge-nesis induced by colon cancer cells.Cel 1,1998,93(5) :705-716．
153． Sell R,Baltimore D Inducitbility of kappa immunoglobulin enhancerbinling protein NF-kappa by a post-translational mechanism.Cell.1986,47:92 1-928．
154． Baeuerle PA,Henkei T.Function and activation of NF-kappa B in theimmune system[J].Annu Rev Immunol,1 994,12:141-179
155． Goebeler M,et al.Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyteprotein-1 gene in primary endothelial cells[J]Blood,2001,97(1) :46-55
156． Ghosh G.NF-kappa B and RPJ pmteins:evolutionary conserved mediators of the immune response.Annu Rev Inmmunol,1998,16:225．
157． Gawaz M,Brand K,Dickfeld T ,et al .Platelets induce alterations ofchemotactic and adhesive properties of endotheiial cells mediated through an interleukin dependent mechanism.Implications for atherogenesis[J].Atherogenesis,2000,148:75-851
158． Wong CK,Ip WK Lam CW.Interleukin,and granulocyte macrophage colony-stimulating factor-induced adhesion molecule ex pression on eosinophils by mitogen-activated protein kinase andnuclear factor kappa B[J].American Journal of Respiratory Cell & Molecular Biology ,2003,29(1) :143-147
159． Gorgoulis VG,Zacharatos P,Kotsinas A,et al.activates ICAM-1(CD54) expression in an NF.KappaB.independent manner[J]EM2 BO Journal 2003 ,22(7) :1567-15781
160． Salvemini D,Manning PT,Zweifel BS,et al.Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties of nitric oxide synthase inhibitors.J Clin Invest,1995,96(1) :301-308．
161． Jarvinen TA,Moilanen T,Jarvinen TL,et al.Endogenous nitric oxide and prosta-glandin E_2 do not regulate the synthesis of each other in interleukin-1 betasti-mulated rat articular cartilage.Inflammation,1996,20(6) :683-692．